Please login to the form below
phase 2 trial
This page shows the latest phase 2 trial news and features for those working in and with pharma, biotech and healthcare.
Sanofi reports positive new data for multiple sclerosis treatment tolebrutinib
phase 2 MS trial design for SAR443820, Sanofi’s investigational oral RIPK1 inhibitor. ... The company has since discontinued its phase 3 URSA trial of tolebrutinib in patients with moderate-to-severe myasthenia gravis, as announced in its
Latest news
-
Gilead’s Trodelvy shows promise in phase 2 bladder cancer study
Gilead Sciences has reported positive results from a phase 2 trial of its Trop-2 directed antibody-drug conjugate Trodelvy (sacituzumab govitecan-hziy) in urothelial cancer (UC), the most common type ... Trodelvy has the potential to become a cornerstone
-
GSK and Vir Biotech amend COVID-19 research partnership
The companies will still continue to work together on their SARS-CoV-2-targeting antibody, sotrovimab, in markets where it is authorised, as well as their experimental COVID-19 antibody, ... This includes the phase 2 PENINSULA trial evaluating VIR-2482
-
FDA gives orphan drug status to Avidity’s rare muscular dystrophy treatment
Now, AOC 1020 is being evaluated in the phase 1/2 FORTITUDE clinical trial in adults with FSHD, with the company expecting to share preliminary data from around half of the ... Avidity announced positive results from its phase 1/2 trial of AOC 1001 in
-
GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis
It also outlined plans to initiate a phase 2/3 trial of Benlysta for SSc associated with ILD in the first half of this year.
-
Boehringer reports positive phase 2 data for spesolimab in generalised pustular psoriasis
The antibody was most recently approved by the European Commission in December 2022 for this indication, a decision supported by results from the phase 2 EFFISAYIL 1 trial. ... These results support positive results from the previous phase 2 study in the
More from news
Approximately 0 fully matching, plus 383 partially matching documents found.
Latest Intelligence
-
Well-funded life sciences firms are making long-term progress – and their investors are too
As of 20 July, Synairgen revealed positive phase 2 trial results. ... share price on the day of the trial.
-
Guiding star of science leads AstraZeneca to breakthrough in child tumour therapy
Selumetinib was given ‘breakthrough therapy’ status and rapidly green-lit by the FDA last month (April) following a promising National Cancer Institute (NCI) Cancer Therapy Evaluation Program sponsored phase 2 trial. ... With the latest phase 2 data,
-
Developing a COVID-19 vaccine
To win approval for public use, a larger phase 2 trial is need, which Moderna says is already in the planning stages and could start within a few months. ... The EMA has acknowledged the impact the pandemic may have on clinical trails and trial
-
Rethinking trials: the pros and cons of protocol amendments
AstraZeneca spokesman Matthew Kent said: “The BICLA was chosen as the primary endpoint for TULIP 2, following a full evaluation of the previous phase e trial TULIP 1, which did not ... The patient sampling size increases, as well, increasing the
-
Integrating patient reported outcomes into clinical trials
MyoKardia is gathering PROs in its phase 2 hypertrophic cardiomyopathy trial. ... Cara Therapeutics put two questionnaires about itching at the centre of its phase 3 pruritus trial.
More from intelligence
Approximately 0 fully matching, plus 13 partially matching documents found.
Latest from PMHub
-
Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)
In its earlier phase 1 monotherapy trial, TAVO demonstrated a 46% response rate in untreated lesions in metastatic melanoma. ... Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Manager
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- MHRA to introduce new UK clinical trials framework
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Janssen’s single tablet combination shows promise in phase 3 PAH study
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- How to make sure your adverts for clinical trials are compliant
PMHub
Say Communications
We focus on what matters most…. Driven by insight, expertise and fresh thinking, our award-winning communications programmes are designed to...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
